Description

PNC-27 Vials

Introduction

Featuring the highest-quality PNC-27 peptide exclusively tailored for research endeavors. Whether your focus is on investigating cancer therapies, delving into cell signaling pathways, or exploring immune responses, this peptide stands as an indispensable resource, empowering advancements in research across these crucial domains.

Key Characteristics

PNC-27 Vials contain a specific peptide sequence, PNC-27, known for its unique molecular structure. This peptide is synthetically derived and undergoes stringent quality control measures to ensure purity and consistency in research settings.

Research Applications

The primary research application of PNC-27 Vials lies in the study of cancer treatment modalities. Researchers can employ this product to investigate the interactions between the PNC-27 peptide and cancer cells, aiming to understand its mechanism of action and potential therapeutic implications.

Research Benefits

PNC-27 Peptide May Destroy Cancer Cells

Research studies have suggested that the PNC-27 peptide demonstrates promising properties in targeting and potentially destroying cancer cells. Various in vitro experiments have shown that PNC-27 may induce apoptosis in specific cancer cell lines, making it a subject of interest for further exploration in cancer research.

Summary

PNC-27 Vials present a valuable tool for cancer research, offering a carefully formulated peptide, PNC-27, for in-depth investigations into its potential to combat cancer cells. With a focus on rigorous research applications, this product contributes to the ongoing scientific exploration of novel cancer treatment avenues.

References

1. Davitt K, Babcock BD, Fenelus M, Poon CK, Sarkar A, Trivigno V, Zolkind PA, Matthew SM, Grin’kina N, Orynbayeva Z, Shaikh MF, Adler V, Michl J, Sarafraz-Yazdi E, Pincus MR, Bowne WB. The anti-cancer peptide, PNC-27, induces tumor cell necrosis of a poorly differentiated non-solid tissue human leukemia cell line that depends on expression of HDM-2 in the plasma membrane of these cells. Ann Clin Lab Sci. 2014 Summer;44(3):241-8. PMID: 25117093. [Read More]
2. Davitt K, Babcock BD, Fenelus M, Poon CK, Sarkar A, Trivigno V, Zolkind PA, Matthew SM, Grin’kina N, Orynbayeva Z, Shaikh MF, Adler V, Michl J, Sarafraz-Yazdi E, Pincus MR, Bowne WB. The anti-cancer peptide, PNC-27, induces tumor cell necrosis of a poorly differentiated non-solid tissue human leukemia cell line that depends on expression of HDM-2 in the plasma membrane of these cells. Ann Clin Lab Sci. 2014 Summer;44(3):241-8. PMID: 25117093. [Read More]
3. Catalina Soriano-Correa, Micheel Merari Vichi-Ramírez, Edtson E. Herrera-Valencia, Carolina Barrientos-Salcedo, The role of ETFS amino acids on the stability and inhibition of p53-MDM2 complex of anticancer p53-derivatives peptides: Density functional theory and molecular docking studies, Journal of Molecular Graphics and Modelling, 122, (108472), (2023).https://doi.org/10.1016/j.jmgm.2023.108472 [Read More]